Document Detail


Misoprostol: an effective agent for cervical ripening and labor induction.
MedLine Citation:
PMID:  7778637     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Our purpose was to compare the safety and efficacy of intravaginal misoprostol versus intracervical prostaglandin E2 gel (dinoprostone) for preinduction cervical ripening and induction of labor. STUDY DESIGN: Two hundred seventy-six patients with indications for induction of labor and unfavorable cervices were randomly assigned to receive either intravaginal misoprostol or intracervical dinoprostone. Twenty-five micrograms of misoprostol were placed in the posterior vaginal fornix every 3 hours, with a potential maximum of eight doses. Prostaglandin E2 in gel form, 0.5 mg, was placed in the endocervix every 6 hours, with a maximum of three doses. Further medication was withheld with the occurrence of spontaneous rupture of membranes, entry into active phase of labor, or a "prolonged contraction response." RESULTS: Among those evaluated, 138 received misoprostol and 137 received dinoprostone. The average interval from start of induction to vaginal delivery was shorter in the misoprostol group (1323.0 +/- 844.4 minutes) than in the dinoprostone group (1532.4 +/- 706.5 minutes) (p < 0.05). Need for oxytocin augmentation of labor occurred more commonly in the dinoprostone group (72.6%) than in the misoprostol group (45.7%) (p < 0.0001). There were no significant differences in the routes of delivery. Twenty-eight of the misoprostol-treated patients (20.3%) and thirty-eight of the dinoprostone-treated patients (27.7%) required abdominal delivery. Complications such as uterine tachysystole and thick meconium passage occurred with similar frequency in the two treatment groups. CONCLUSIONS: Intravaginal administration of misoprostol appears to be as effective as intracervical dinoprostone for cervical ripening and labor induction. Complications associated with prostaglandin administration were not statistically different between the two treatment groups. The cost of misoprostol ($0.36/100 micrograms) is much less than that of dinoprostone ($75/0.5 mg).
In a comparative study conducted in 1994 among 276 women presenting to a Los Angeles, California (US), hospital with indications for induction of labor but unfavorable cervices, intravaginal administration of misoprostol was as effective as intracervical prostaglandin E2 gel (dinoprostone) for cervical ripening and labor induction. 138 women were randomly assigned to receive 25 mcg of misoprostol placed in the posterior vaginal fornix every 3 hours (maximum of 8 doses), while 137 were given 0.5 mg dinoprostone placed in the endocervix every 6 hours (maximum of 3 doses). The average interval from start of induction to vaginal delivery was 1323 +or- 844.4 minutes in the misoprostol group compared with 1532 +or- 706.5 minutes in the dinoprostone group. 45.7% of women in the misoprostol group compared with 72.6% in the dinoprostone group required oxytocin augmentation of labor. The goal of vaginal delivery within 24 hours was achieved by 65.5% of women in the misoprostol group, but only by 41.4% of those in the dinoprostone group. The cesarean section rates were 20.3% and 27.7%, respectively. Complications such as uterine tachysystole and meconium passage occurred with similar frequency in both groups. These findings suggest that misoprostol is a safe, effective, and inexpensive (US$0.36 per tablet) agent for cervical ripening and labor induction.
Authors:
D A Wing; A Rahall; M M Jones; T M Goodwin; R H Paul
Related Documents :
9249857 - Anaesthesia and basic experimental surgery of minipigs. a practical exercise.
11867397 - Spinal ropivacaine for cesarean delivery: a comparison of hyperbaric and plain solutions.
3300427 - Comparison of halothane and isoflurane for rapid anesthetic induction.
11867377 - Physostigmine does not antagonize sevoflurane anesthesia assessed by bispectral index o...
11307867 - Pulmonary complications of obesity.
22588047 - Acute dietary nitrate supplementation improves dry static apnea performance.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  172     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  1995 Jun 
Date Detail:
Created Date:  1995-07-13     Completed Date:  1995-07-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1811-6     Citation Subset:  AIM; IM; J    
Affiliation:
Department of Obstetrics and Gynecology, Los Angeles County-University of Southern California Medical Center 90033, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cervix Uteri / drug effects,  physiology*
Cesarean Section
Dinoprostone / adverse effects,  therapeutic use
Female
Humans
Labor, Induced*
Misoprostol / administration & dosage,  adverse effects,  therapeutic use*
Oxytocin / administration & dosage,  therapeutic use
Pregnancy
Pregnancy Outcome
Time Factors
Uterine Contraction / drug effects
Chemical
Reg. No./Substance:
363-24-6/Dinoprostone; 50-56-6/Oxytocin; 59122-46-2/Misoprostol
Comments/Corrections
Comment In:
Am J Obstet Gynecol. 1996 Feb;174(2):797   [PMID:  8623826 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A comparison of misoprostol and prostaglandin E2 gel for preinduction cervical ripening and labor in...
Next Document:  Ureteral injury in gynecologic surgery: a ten-year review in a community hospital.